Biotech catalyst, news and analysis PDUFA tracker
Tickers reports and analysis
RUSSELL 2026 PRELIMINARY LIST 87 HEALTH CARE ADDITIONS BIOTECH FOCUS Russell 2026 Biotech Watchlist: $UNCY, $GALT, $SPRB, $OVID and the Small-Cap Health Care Additions to Watch The June 2026 Russell reconstitution becomes effective after the U.S. market close on June…
Three healthcare small caps enter the morning radar for different reasons: Pulsenmore is pushing FDA-authorized home ultrasound into U.S. virtual maternity care, IceCure is building the clinical-validation story around ProSense cryoablation, and Silence Therapeutics is moving closer to a Phase 2 SANRECO readout for divesiran in polycythemia vera.
The FDA approval of TRYNGOLZA in adults with severe hypertriglyceridemia turns olezarsen from a rare-disease FCS launch into a broader cardiometabolic commercial story. The key issue now is not simply whether the drug works, but how quickly Ionis can convert a stronger label, a larger addressable population and pancreatitis-risk messaging into real prescribing momentum.
Phase 3 clinical data, analyst coverage and an international licensing deal: three real, verified catalysts across DFTX, ABSI and NVCT.
A verified deep dive on Annamycin, the MIRACLE Phase 2b/3 trial, the latest cardiac-safety package, the company’s fragile cash position, and the binary scenarios surrounding the first 45-subject interim unblinding expected by June 30, 2026.
Three biotech updates hit the tape today with very different market meanings: Taysha delivered the strongest clinical/regulatory signal, Entera Bio reduced Phase 3 design uncertainty around EB613, and Scholar Rock added a near-term neuromuscular conference watch around SMA and FSHD
Definium has moved from a speculative late-stage psychedelic psychiatry story into a much more serious Phase 3 data story. The positive Emerge readout in major depressive disorder changes the market conversation around DT120 ODT, but it does not remove the key risks: replication, regulatory execution, controlled-substance scheduling, commercial infrastructure, reimbursement and future capital strategy.
Addex Therapeutics, Definium Therapeutics, MoonLake Immunotherapeutics and CEL-SCI do not belong to the same biotech story. But today’s updates show four very different types of biotech catalysts: a financial and pipeline update, a Phase 3 psychiatry readout event, long-term immunology data tied to a future BLA strategy, and an international commercialization pathway for an investigational oncology asset.
Educational report – business, clinical, financial and scenario analysis for Aurinia Pharmaceuticals after CEO Kevin Tang's large indirect insider purchase (~$12.46M), the EULAR 2026 LUPKYNIS data, and the reassessment of the former Kezar pipeline.
Three biotech catalyst stories are converging at the end of June: Spero/GSK have moved from binary FDA risk to Utebzi approval follow-through; Achieve Life Sciences has shifted from a clean PDUFA calendar story to a manufacturing-related resubmission path; and Viridian Therapeutics is approaching a June 30 FDA target action date for veligrotug in thyroid eye disease. The common thread is simple: in catalyst biotech, the calendar matters — but the label, manufacturing path, economics, launch readiness and balance sheet matter even more.
Two FDA approvals in the same March 2026 window. Two Priority Review Voucher monetizations. One common theme: fresh non-dilutive cash that materially changes the financial runway debate for both companies.
Soquelitinib, an oral selective ITK inhibitor, has shown encouraging clinical signals even in patients with prior systemic therapy exposure, including cases non-responsive to dupilumab or JAK inhibitors. With $236.7M in cash as of March 31, 2026, a company-stated runway into Q2 2028 in corporate communications, and an ongoing oncology Phase 3, CRVS remains a catalyst-heavy biotech story.
The AMT-130 story has moved from enthusiasm, to regulatory shock, to a sudden reopening of the U.S. accelerated approval path. The key issue now is whether uniQure can convert today’s FDA reversal into a credible Q3 2026 BLA submission and, eventually, a first disease-modifying therapy for Huntington’s disease.
$JAZZ $ABCL Official Partnership Deal T-Cell Engagers Jazz Pharmaceuticals + AbCellera ($JAZZ $ABCL): T-Cell Engager Partnership and Competitive Oncology Landscape A complete deep dive into Jazz Pharmaceuticals’ collaboration with AbCellera to discover next-generation T-cell engaging multispecific antibodies for gastrointestinal cancers…
Moderna’s seasonal flu vaccine story has changed sharply. The previous setup was built around a refusal-to-file shock and a PDUFA clock that never started. Now the same asset is heading into a public FDA advisory committee, with a formal August decision date, a reorganized commercial leadership structure, and a stock narrative that has moved from “regulatory roadblock” to “high-stakes execution window.”
Phase 3 enrollment completed with 1,939 patients across 43 countries, topline data expected Q4 2026: barzolvolimab has the potential to redefine the standard of care in a disease affecting more than 1.8 million patients in the United States according to Celldex, with a narrower biologic-eligible subpopulation.
Neumora’s June 15, 2026 update turns the $NMRA story into a cleaner but more unforgiving special situation: the former lead depression asset has now failed across the Phase 3 KOASTAL program, the company is discontinuing navacaprant, cutting approximately 35% of its workforce and trying to preserve enough runway to prove whether the remaining neuroscience pipeline can still justify investor attention.
After the collapse of Relyvrio in ALS, Amylyx is rebuilding its equity story around avexitide, a GLP-1 receptor antagonist being developed for post-bariatric hypoglycemia, a serious complication after bariatric surgery with no FDA-approved therapy. The pivotal LUCIDITY Phase 3 readout is expected in Q3 2026.
Unicycive, Spero and Capricor are approaching three very different regulatory moments: a phosphate-binder resubmission for dialysis patients, a partnered oral carbapenem opportunity in complicated urinary tract infection, and a rare-disease cell therapy review in Duchenne muscular dystrophy. The common thread is simple: each story now has a dated FDA catalyst, a defined risk window and a market setup that demands precision rather than hype.
From the $0.23 post-CRL low to an FDA Formal Dispute Resolution victory — a narrative deep dive into how OTLK collapsed, survived, and what comes next with the LYTENAVA US BLA and the expected late July / early August 2026 FDA decision window.
